With $46 million in Series A funding, i2o Therapeutics is taking another run at approval of a drug-device combination licensed from Intarcia.Former biotechnology unicorn Intarcia Therapeutics is getting a new life less than a month before a panel of Food and Drug Administration advisers could decide the fate of the diabetes treatment it’s spent more […]
